Novocure Announces LUNAR Pivot Study in Non-Small Cell Lung Cancer Achieves Primary Endpoint of Overall Survival

Lung Cancer

The LUNAR trial’s primary goal was fulfilled, according to Novocure, showing a statistically and clinically meaningful increase in overall survival when compared to standard therapy alone. Stage 4 non-small cell lung cancer (NSCLC) that has progressed during or following platinum therapy is the focus of the open-label, randomised LUNAR research, which compares the safety and effectiveness of TTFields therapy with other treatments.

The LUNAR study also showed a statistically and clinically significant improvement in overall survival when patients were treated with TTFields in combination with immune checkpoint inhibitors (ICIs), as opposed to when immune checkpoint inhibitors were treated alone, as well as a favourable trend in overall survival when patients were treated with TTFields and docetaxel as opposed to docetaxel alone. In the experimental and control arms, patient enrolment was evenly split between the ICI and docetaxel cohorts; the control arms were consistent with earlier research. Patients who participated in the experimental portion of the trial tolerated TTFields therapy well.

“We are pleased with the positive results from the LUNAR study. Prior to LUNAR, the most recent phase 3 study leading to a significant improvement in overall survival in advanced, platinum-resistant non-small cell lung cancer was six years ago , and this underscores the difficulty of treating this disease”, “We are also pleased by the excellent performance of TTFields in combination with immunotherapy, potentially able to significantly prolong patient survival compared to previously possible. I would like to thank our patients and researchers for the courage and dedication with which they have completed LUNAR and Novocure employees for the

William Doyle, executive director of Novocure

The complete LUNAR research results are anticipated to be released by Novocure at a future medical conference. In the second half of 2023, Novocure wants to submit a pre-market approval application to the U.S. Food and Drug Administration (FDA). The business also intends to submit a CE mark application to the European Union at the same time.

Next Post

What's new from RSNA 2022

In this first webinar you will hear from David Spagnoli, the Upstream Product Marketing Leader at Philips who will set the stage for the webinars to follow in this series, while providing a brief overview of the latest innovations from Philips MR as a follow-up to RSNA 2022.
Featured Video Play Icon